Recombinant live Salmonella spp. for human vaccination against heterologous pathogens.
Live attenuated Salmonella spp. are promising candidates as oral vaccine delivery systems for heterologous antigens. Clinical trials have demonstrated that this approach is feasible for human vaccinations but further optimisation is necessary to obtain a better efficacy. Here, we discuss how existing clinical and pre-clinical data can be used to guide such optimisation efforts.
Bumann
D
D
Max-Planck-Institut für Infektionsbiologie, Abt. Molekulare Biologie, Monbijoustrasse 2, D-10117, Berlin, Germany.
Hueck
C
C
Aebischer
T
T
Meyer
T F
TF
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D001424:Bacterial Infections / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D051379:Mice; D011994:Recombinant Proteins / Q000276:immunology; D012485:Salmonella typhi / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D011994:Recombinant Proteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic